AllSquare Wealth Management LLC cut its stake in shares of Celgene Co. (NASDAQ:CELG) by 18.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,396 shares of the biopharmaceutical company’s stock after selling 550 shares during the quarter. AllSquare Wealth Management LLC’s holdings in Celgene were worth $349,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Arcadia Investment Management Corp MI lifted its position in Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the period. Thompson Davis & CO. Inc. lifted its position in Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the period. Guidant Wealth Advisors acquired a new stake in Celgene in the third quarter worth approximately $119,000. Motco lifted its position in Celgene by 19.3% in the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the period. Finally, Balentine LLC lifted its position in Celgene by 83.5% in the second quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 481 shares during the period. 79.74% of the stock is owned by institutional investors.

Celgene Co. (NASDAQ CELG) opened at $105.46 on Thursday. The firm has a market cap of $83,030.00, a price-to-earnings ratio of 24.87, a PEG ratio of 0.68 and a beta of 1.77. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.58 EPS. research analysts anticipate that Celgene Co. will post 6.68 EPS for the current year.

A number of brokerages have recently commented on CELG. Stifel Nicolaus set a $130.00 price objective on Celgene and gave the company a “buy” rating in a research report on Monday. SunTrust Banks set a $127.00 target price on Celgene and gave the company a “buy” rating in a report on Monday. Guggenheim restated a “buy” rating and issued a $147.00 target price on shares of Celgene in a report on Wednesday. Oppenheimer set a $166.00 target price on Celgene and gave the company a “buy” rating in a report on Monday. Finally, Credit Suisse Group set a $125.00 target price on Celgene and gave the company a “buy” rating in a report on Monday. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have given a buy rating to the stock. Celgene currently has a consensus rating of “Buy” and a consensus target price of $131.18.

TRADEMARK VIOLATION WARNING: “AllSquare Wealth Management LLC Sells 550 Shares of Celgene Co. (CELG)” was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/allsquare-wealth-management-llc-sells-550-shares-of-celgene-co-celg/1802259.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.